These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 1199816)

  • 1. Intestinal decarboxylation of orally administered L-dopa. Influence of pharmacological preparations, dose magnitude, dose sequence and food intake.
    Andersson I; Granerus AK; Jagenburg R; Svanborg A
    Acta Med Scand; 1975 Nov; 198(5):415-20. PubMed ID: 1199816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Variations in L-dopa absorption. Report of a parkinsonian patient with high plasma dopa concentration after therapeutical L-dopa dose.
    Granerus AK; Jagenburg R; Rödjer S; Svanborg A
    Acta Med Scand; 1974 Dec; 196(6):459-63. PubMed ID: 4456974
    [No Abstract]   [Full Text] [Related]  

  • 3. [The L-dopa test in Parkinson's disease].
    Esteguy M; Bonnet AM; Kefalos J; Lhermitte F; Agid Y
    Rev Neurol (Paris); 1985; 141(5):413-5. PubMed ID: 4048732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Slow-release L-dopa vs. standard L-dopa in Parkinson patients in various stages of the disease. Studies of pharmacokinetics and motor effectiveness].
    Bergemann N; Baas H; Fischer PA
    Nervenarzt; 1994 Apr; 65(4):250-7. PubMed ID: 8015632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effectiveness of slow release L-DOPA/benserazide in treatment of end-of-dose akinesia in Parkinson disease].
    Eichhorn TE; Schrag A; Trenkwalder C; Selzer R; Kohnen R; Oertel WH; Poewe W
    Nervenarzt; 1995 Dec; 66(12):933-41. PubMed ID: 8584079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Homocysteine levels after acute levodopa intake in patients with Parkinson's disease.
    Müller T; Kuhn W
    Mov Disord; 2009 Jul; 24(9):1339-43. PubMed ID: 19425084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of cisapride on plasma L-dopa levels and clinical response in Parkinson's disease.
    Neira WD; Sanchez V; Mena MA; de Yebenes JG
    Mov Disord; 1995 Jan; 10(1):66-70. PubMed ID: 7885357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Favorable effect of catechol-O-methyltransferase inhibition by OR-462 in experimental models of Parkinson's disease.
    Lindén IB; Nissinen E; Etemadzadeh E; Kaakkola S; Männistö P; Pohto P
    J Pharmacol Exp Ther; 1988 Oct; 247(1):289-93. PubMed ID: 3171977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intermittent levodopa therapy in parkinsonism.
    Koller WC
    Adv Neurol; 1983; 37():45-50. PubMed ID: 6407286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous boluses and continuous infusions of L-dopa methyl ester in fluctuating patients with Parkinson's disease.
    Stocchi F; Ruggieri S; Carta A; Ryatt J; Quinn N; Jenner P; Marsden CD; Agnoli A
    Mov Disord; 1992; 7(3):249-56. PubMed ID: 1620143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of a normal protein diet on levodopa plasma kinetics in advanced Parkinson's disease.
    Simon N; Gantcheva R; Bruguerolle B; Viallet F
    Parkinsonism Relat Disord; 2004 Mar; 10(3):137-42. PubMed ID: 15036167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis.
    Merello M; Nouzeilles MI; Arce GP; Leiguarda R
    Mov Disord; 2002 Jul; 17(4):795-8. PubMed ID: 12210878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of piribedil in early combination with L-dopa in the treatment of Parkinson's disease: a 6-month open study.
    Suwantamee J; Nidhinandana S; Srisuwananukorn S; Laptikultham S; Pisarnpong A; Chankrachang S; Bundhukul A
    J Med Assoc Thai; 2004 Nov; 87(11):1293-300. PubMed ID: 15825702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Absorption, excretion, and clinical effects of L-dopa preparation with superenteric coating in parkinsonism (author's transl)].
    Tohgi H; Ogawa M
    No To Shinkei; 1977 Aug; 29(8):873-8. PubMed ID: 907761
    [No Abstract]   [Full Text] [Related]  

  • 16. [Trans-cerebral electrophoresis of L-DOPA in the complex treatment of parkinsonism].
    Neĭmark EZ; Evtushenko SK; Dukhovnaia MA
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1984; 84(9):1334-8. PubMed ID: 6506979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Tandospirone citrate, a selective 5-HT1A agonist, alleviates L-DOPA-induced dyskinesia in patients with Parkinson's disease].
    Kannari K; Kurahashi K; Tomiyama M; Maeda T; Arai A; Baba M; Suda T; Matsunaga M
    No To Shinkei; 2002 Feb; 54(2):133-7. PubMed ID: 11889759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A new levodopa benserazide preparation for Parkinson's disease with motor fluctuations refractory to standard L-dopa].
    Fernández Pardal MM; Gatto E; Micheli F; Casas Parera I; Diaz S
    Medicina (B Aires); 1991; 51(6):561-7. PubMed ID: 7476112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute vs chronic effects of l-dopa on bladder function in patients with mild Parkinson disease.
    Brusa L; Petta F; Pisani A; Moschella V; Iani C; Stanzione P; Miano R; Finazzi-Agrò E
    Neurology; 2007 May; 68(18):1455-9. PubMed ID: 17470746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response to L-dopa and evolution of motor fluctuations in the early phase of treatment of Parkinson's disease.
    Shif M; Kempster PA
    Clin Exp Neurol; 1994; 31():38-42. PubMed ID: 7586663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.